CO70 Matching Adjusted Indirect Comparison (MAIC) of Single Tremelimumab Regular Interval Durvalumab (STRIDE) Versus Atezolizumab with Bevacizumab (A+B) for the Treatment of Unresectable Hepatocellular Carcinoma (UHCC)

L Qin,S Chan,P Le Nouveau,A Gaughan,A Gauthier,M Makowsky,J Kurland,A Negro,S Palmer

doi:10.1016/j.jval.2023.03.144

CO70 Matching Adjusted Indirect Comparison (MAIC) of Single Tremelimumab Regular Interval Durvalumab (STRIDE) Versus Atezolizumab with Bevacizumab (A+B) for the Treatment of Unresectable Hepatocellular Carcinoma (UHCC)

L Qin, S Chan + Show 7 more

https://doi.org/10.1016/j.jval.2023.03.144

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jun 1, 2023
Citations: 1

Affiliation: AstraZeneca (United States), Chinese University of Hong Kong, Eticas Research & Consulting (Spain), University of York

#Matching Adjusted Indirect Comparison #Treatment Of Unresectable Hepatocellular Carcinoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

STRIDE and A+B demonstrated superiority vs sorafenib (S) for overall survival (OS), with median follow-up times of 33.2m and 15.6m, respectively. As there are no trials comparing these two regimens, this analysis estimated the comparative efficacy and safety of STRIDE vs A+B, based on the HIMALAYA and IMbrave 150 clinical trials.

Full Text